Digital spatial profiling for pathologists
- PMID: 39499318
- DOI: 10.1007/s00428-024-03955-w
Digital spatial profiling for pathologists
Abstract
The advent of "omics" technologies for high-depth tumor profiling has provided new information regarding cancer heterogeneity. However, a bulk omics profile can only partially reproduce tumor complexity, and it does not meet the preferences of pathologists used to perform an in situ assessment of marker expression, for instance, with immunohistochemistry. The NanoString GeoMx® Digital Spatial Profiler (DSP) is a platform for morphology-guided multiplex profiling of tissue slides, which allows the digital quantification of target analytes in different neoplastic settings. To illustrate the feasibility and opportunities offered by DSP from a pathologist's perspective, we applied DSP in three different representative neoplastic settings: breast carcinoma, thyroid anaplastic carcinoma, and biphasic mesothelioma. Because of the perfect overlap between the hematoxylin-eosin-stained slide and the GeoMx areas of interest, in breast carcinoma, two different antibodies allowed the distinction of the tumor cells from the surrounding tumor microenvironment. In biphasic mesothelioma, we could distinguish the epithelioid from the sarcomatoid neoplastic component, and in the thyroid, we easily separated the anaplastic areas from the well-differentiated carcinoma. DSP is a promising tool that combines traditional histological evaluation, allowing spatial assessment of a tumor and its surroundings, and innovative in situ digital profiling. Pathologists should not miss the opportunity to combine morphological and genomic analyses and be at the forefront of investigating the progression of dysplasia/neoplasia, low-grade or high-grade, epithelial/mesenchymal, and, more in general, overcoming the concept of in situ vs. bulk genomic methods.
Keywords: Digital spatial profiling; Hematoxylin–eosin; Surgical pathology; Tissue slides.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee (protocol number: 2020/0011853 – 2023/0003839–2020/0063362). Conflict of interest: The authors declare no competing interests.
References
-
- Beechem JM (2020) High-plex spatially resolved RNA and protein detection using digital spatial profiling: a technology designed for immuno-oncology biomarker discovery and translational research. In: Thurin M, Cesano A, Marincola F (eds) Biomarkers for immunotherapy of cancer. Methods in Molecular Biolog 2055. Humana, New York, NY, USA. https://doi.org/10.1007/978-1-4939-9773-2_25
-
- Rahman A, Jahangir C, Lynch SM et al (2020) Advances in tissue-based imaging: impact on oncology research and clinical practice. Expert Rev Mol Diagn 20:1027–1037. https://doi.org/10.1080/14737159.2020.1770599 - DOI - PubMed
-
- Marx V (2021) Method of the year: spatially resolved transcriptomics. Nat Methods 18:9–14. https://doi.org/10.1038/s41592-020-01033-y - DOI - PubMed
-
- Blank CU, Rozeman EA, Fanchi LF et al (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 24:1655–1661. https://doi.org/10.1038/s41591-018-0198-0 - DOI - PubMed
-
- Amaria RN, Reddy SM, Tawbi HA et al (2018) Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24:1649–1654. https://doi.org/10.1038/s41591-018-0197-1 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous